Experimental GLP-1 pill helped people with diabetes lose weight and lower blood sugar, Eli Lilly says

An experimental oral medication from Eli Lilly, a GLP-1 receptor agonist named orforglipron, has shown promising results in a mid-stage clinical trial for people with type 2 diabetes. The trial, involving 302 participants, demonstrated that the pill effectively lowered blood sugar levels and facilitated weight loss, with participants losing between 3.3 to 8.6 pounds on average, depending on the dosage, compared to a weight gain of 1.1 pounds in the placebo group. The drug was well-tolerated, with the most common side effects being mild to moderate gastrointestinal issues. These findings suggest that orforglipron could be a convenient alternative to injectable GLP-1 therapies, potentially offering a new treatment option for managing type 2 diabetes and aiding weight loss.

Read the Full CNN Article at:
[ https://www.msn.com/en-us/health/other/experimental-glp-1-pill-helped-people-with-diabetes-lose-weight-and-lower-blood-sugar-eli-lilly-says/ar-AA1D67op ]